BioNTech SE (NASDAQ:BNTX – Get Rating) has been given a consensus rating of "Hold" by the seventeen analysts that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $231.43.
Several analysts recently issued reports on BNTX shares. The Goldman Sachs Group set a $200.00 price target on shares of BioNTech in a research report on Tuesday, August 9th. Cowen started coverage on shares of BioNTech in a research report on Wednesday, August 17th. They issued a "market perform" rating and a $177.00 target price on the stock. Canaccord Genuity Group raised their target price on shares of BioNTech from $192.00 to $200.00 and gave the company a "buy" rating in a research report on Tuesday, August 9th. Canaccord Genuity Group restated a "buy" rating and issued a $192.00 target price on shares of BioNTech in a research report on Wednesday, July 6th. Finally, UBS Group set a $168.00 target price on shares of BioNTech in a research report on Thursday, June 30th.
Get BioNTech alerts:BioNTech Trading Down 1.3 %
Shares of NASDAQ:BNTX opened at $128.35 on Monday. BioNTech has a 52-week low of $117.08 and a 52-week high of $374.58. The company has a market capitalization of $31.15 billion, a P/E ratio of 2.48 and a beta of 0.03. The company has a 50-day simple moving average of $152.89 and a 200 day simple moving average of $154.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.06 and a current ratio of 5.15.
BioNTech (NASDAQ:BNTX – Get Rating) last announced its earnings results on Monday, August 8th. The company reported $6.45 EPS for the quarter, missing the consensus estimate of $7.08 by ($0.63). The business had revenue of $3.20 billion for the quarter, compared to the consensus estimate of $4.11 billion. BioNTech had a return on equity of 88.76% and a net margin of 55.43%. The firm's revenue for the quarter was down 39.8% compared to the same quarter last year. During the same period in the prior year, the business posted $12.98 earnings per share. Sell-side analysts forecast that BioNTech will post 33.27 earnings per share for the current year.Institutional Investors Weigh In On BioNTech
Several hedge funds and other institutional investors have recently made changes to their positions in BNTX. Captrust Financial Advisors boosted its stake in BioNTech by 6.9% in the second quarter. Captrust Financial Advisors now owns 1,068 shares of the company's stock valued at $159,000 after acquiring an additional 69 shares during the last quarter. Centaurus Financial Inc. boosted its stake in shares of BioNTech by 5.2% in the 1st quarter. Centaurus Financial Inc. now owns 1,448 shares of the company's stock valued at $247,000 after purchasing an additional 71 shares in the last quarter. Exane Derivatives boosted its stake in shares of BioNTech by 13.5% in the 2nd quarter. Exane Derivatives now owns 799 shares of the company's stock valued at $119,000 after purchasing an additional 95 shares in the last quarter. KRS Capital Management LLC purchased a new stake in shares of BioNTech in the 4th quarter valued at $25,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in BioNTech by 66.7% during the 1st quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 250 shares of the company's stock valued at $43,000 after buying an additional 100 shares during the period. 13.77% of the stock is owned by institutional investors.
About BioNTech
(Get Rating)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.
Further Reading
- Get a free copy of the StockNews.com research report on BioNTech (BNTX)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.